Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Exp Neurol. 2016 Feb 15;279:13–26. doi: 10.1016/j.expneurol.2016.02.009

Figure 3. The effects of administration of VX563 on survival of SMNΔ7 SMA mice beginning at PND09.

Figure 3

SMNΔ7 SMA mice were treated daily with VX563 beginning at PND09 and monitored for changes in lifespan (A) and onset of loss of body mass (B). There were no significant changes in the average lifespan (A; p = 0.507) or the onset of body mass loss (B; p = 0.569) between VX563-treated SMNΔ7 SMA mice treated and vehicle-treated SMNΔ7 SMA mice.